Provides custom antibody and protein production services and AI-driven drug discovery tools to biopharmaceutical companies.
20-F for FY2026, filed Jul 23, 2026The Company has a long-standing acceptance of its customized antibodies and protein production services in the market. The Company believes…View ↗
On October 23, 2023, BioStrand’s integrated platform, designed to enhance customers' drug discovery and development, began its limited…View ↗
The development, testing, manufacturing, labeling, storage and approval of antibody and therapeutic products are subject to regulation by…View ↗
Antibody sales are tied to delivery or shipment; contracted services are billed as work progresses based on hours worked, while some contracts are billed when customers accept the finished service.
CAD 15.6M
20-F for FY2026, filed Jul 23, 2026
CAD 15.6M ↗
Biopharmaceutical companies are among its clients; customers buying custom monoclonal or polyclonal antibodies and peptide production work use master service agreements.
20-F for FY2026, filed Jul 23, 2026
Shrinking. Revenue fell 20% in 4 years, from CAD 19.4M in FY2022 to CAD 15.6M in FY2026, about 5% a year.
Competes with Abveris, Genovac, Antibody Solutions, Genscript Biotech, and Lake Pharma
20-F for FY2026, filed Jul 23, 2026As a Bio-Native AI company that combines AI-driven discovery with full-stack wet-lab capabilities, the Company competes both with…View ↗
Loading...